IVX Health is a technology company.
IVX Health has raised $123.0M across 2 funding rounds.
IVX Health has raised $123.0M in total across 2 funding rounds.
IVX Health has raised $123.0M in total across 2 funding rounds.
IVX Health's investors include Health Velocity Capital.
IVX Health is a healthcare provider operating a national network of outpatient infusion centers, delivering biologic infusion and injection therapies for patients with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, and lupus[1][2][3][4][6]. It serves patients seeking convenient alternatives to hospital-based care, solving the problem of crowded, inconvenient infusion settings by offering private suites, flexible scheduling (including evenings and weekends), high-speed Wi-Fi, flat-screen TVs, leather recliners, guest chairs, and a low 1:3 nurse-to-patient ratio—all in community locations like retail centers[1][2][3][4][7]. With over 50 centers across 16 markets as of 2021 and total funding of approximately $166M (including a $100M Series F in 2021 from Great Hill Partners), IVX Health demonstrates strong growth momentum through market expansions, such as new New Jersey clinics, and recognition as one of Modern Healthcare's Best Places to Work in 2024[1][2][7].
IVX Health, based in Brentwood, Tennessee, was founded on the premise that outpatient infusion sites are more effective, cost-efficient, and patient-friendly than hospitals, emerging as an alternative to traditional crowded infusion rooms[1][2][3]. While specific founders are not detailed in available sources, the company has assembled a leadership team with deep healthcare expertise; for instance, Chief Medical Officer Dr. Andrew Lasher joined in 2019, bringing over 20 years of experience, including founding and scaling Aspire Health (sold to Anthem in 2018)[8]. Executive Tate McDaniel, with a background in consumer healthcare at startups like Change Healthcare, was drawn to IVX for its focus on enhancing patient experiences as a direct care provider[5]. Early traction built through a patient-centered model, leading to rapid scaling: by 2021, it operated over 50 centers, secured $100M in growth funding from Great Hill Partners to enter new markets, and adapted with telemedicine during the pandemic for virtual supervision[2][5].
IVX Health rides the trend of outpatient care shift from hospitals to convenient, retail-embedded sites, driven by patient demand for location and experience over insurance, amid shortages of traditional medical space[1]. Timing aligns with rising biologic therapies for chronic conditions and post-pandemic telemedicine adoption, which IVX leveraged for uninterrupted care[2][5]. Market forces favoring it include healthcare cost pressures (outpatient is cheaper), provider shortages, and consumer-like amenities boosting adherence; expansions into states like New Jersey reflect this, with partners like JLL aiding national rollout[1]. It influences the ecosystem by redefining infusion as an "experience-first" service, collaborating with providers, insurers (in-network options), and pharma for broader access, while earning workplace accolades that attract talent[2][4][7].
IVX Health is poised for continued expansion, building on its 2021 funding to add centers in high-demand regions, potentially surpassing 16 markets amid growing chronic disease prevalence and outpatient momentum[1][2]. Trends like AI-enhanced scheduling, further telemedicine evolution, and value-based care will shape its path, enabling efficiencies and deeper insurer partnerships. Its influence may grow as a model for patient-centric specialties, influencing competitors to prioritize amenities and community siting—ultimately fulfilling its vision as the preferred national destination for pharmaceutical care and transforming chronic therapy from a chore to a seamless experience.
IVX Health has raised $123.0M across 2 funding rounds. Most recently, it raised $100.0M Series F in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $100.0M Series F | Health Velocity Capital | |
| Aug 1, 2019 | $23.0M Series C | Health Velocity Capital |